Akari Therapeutics Plc (NASDAQ:AKTX)
| Market Cap | 19.47M-78.9% |
| Revenue (ttm) | 0 |
| Net Income | -30.96M-152.4% |
| EPS | -13.48-27.4% |
| Shares Out | 2.30M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 13,788.449 |
| Open | 8.37 |
| Previous Close | 8.63 |
| Day's Range | 8.35 - 8.77 |
| 52-Week Range | 3.02 - 42.80 |
| Beta | 1.44 |
| Analysts | Buy |
| Price Target | 24.75(+191.86%) |
| Earnings Date | Dec 4, 2026 |
Insiders here have filed 3 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About AKTX
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company’s lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Tampa, Florida.
$AKTX stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in AKTX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by AKTX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
AKTX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New AKTX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to AKTX from public contracts
Source: USAspending.gov
AKTX Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from AKTX’s recent data — informational, not investment advice